术前抗凝血酶补充对心脏手术患者的多中心随机双盲安慰剂对照试验
该多中心随机双盲安慰剂对照试验纳入425例体外循环心脏手术成人患者,评估术前补充抗凝血酶(AT)的安全性和有效性。
要点
- 术前AT补充未降低体外循环心脏手术患者术后主要并发症发生率。
- AT组急性肾损伤发生率显著高于安慰剂组(11.6% vs 2.6%)。
- AT组ICU期间AT活性≥58%的患者比例显著更高(81.5% vs 43.2%)。
核心结论
- 术前抗凝血酶补充未能减少体外循环心脏手术患者术后不良结局。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验,共425例成人患者随机1:1接受单剂AT(n=213)或安慰剂(n=212)术前给药,最终399例纳入分析。
主要发现
- AT输注后AT活性显著高于安慰剂组(108% [42-143] vs 76% [40-110]),持续至术后第2天。
- 次要终点(失血量、输血需求、ICU及住院时间)及安全性(治疗中出现的不良事件、出血事件)组间无差异。
临床怎么用
- 不推荐对体外循环心脏手术患者常规术前补充AT以预防术后并发症。
- 术前AT补充需警惕急性肾损伤风险增加。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antithrombin (AT) activity is reduced during cardiac operations with cardiopulmonary bypass (CPB), which is associated with adverse outcomes. Preoperative AT supplementation, to achieve >58% and <100% AT activity, may potentially reduce postoperative morbidity and mortality in cardiac operations with CPB. This prospective, multicenter, randomized, double-blind, placebo-controlled study was designed to evaluate the safety and efficacy of preoperative treatment with AT supplementation in patients at risk for low AT activity after undergoing cardiac surgery with CPB. METHODS: A total of 425 adult patients were randomized (1:1) to receive either a single dose of AT (n = 213) to achieve an absolute increase of 20% above pretreatment AT activity or placebo (n = 212) before surgery. The study duration was approximately 7 weeks. The primary efficacy end point was the percentage of patients with any component of a major morbidity composite (postoperative mortality, stroke, acute kidney injury [AKI], surgical reexploration, arterial or venous thromboembolic events, prolonged mechanical ventilation, and infection) in the 2 groups. Secondary end points included AT activity, blood loss, transfusion requirements, duration of intensive care unit (ICU), and hospital stays. Safety was also assessed. RESULTS: Overall, 399 patients (men, n = 300, 75.2%) with a mean (standard deviation [SD]) age of 66.1 (11.7) years, with the majority undergoing complex surgical procedures (n = 266, 67.9%), were analyzed. No differences in the percentage of patients experiencing morbidity composite outcomes between groups were observed (AT-treated 68/198 [34.3%] versus placebo 58/194 [29.9%]; P = .332; relative risk, 1.15). After AT infusion, AT activity was significantly higher in the AT group (108% [42-143]) versus placebo group (76% [40-110]), and lasted up to postoperative day 2. At ICU, the frequency of patients with AT activity ≥58% in the AT group (81.5%) was significantly higher ( P < .001) versus placebo group (43.2%). Secondary end point analysis did not show any advantage of AT over placebo group. There were significantly more patients with AKI ( P < .001) in the AT group (23/198; 11.6%) than in the placebo group (5/194, 2.6%). Safety results showed no differences in treatment-emergent adverse events nor bleeding events between groups. CONCLUSIONS: AT supplementation did not attenuate adverse postoperative outcomes in our cohort of patients undergoing cardiac surgery with CPB.
引用
- Moront MG, Woodward MK, Essandoh MK, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Antithrombin Supplementation in Patients at Risk for Antithrombin Deficiency After Cardiac Surgery. Anesth Analg. 2022. PMID: 35877927. doi:10.1213/ANE.0000000000006145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。